{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:21:51Z","timestamp":1777879311594,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016912","name":"MSD France SAS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bulcan.2026.01.019","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T03:06:35Z","timestamp":1774926395000},"page":"619-627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Traitements syst\u00e9miques de premi\u00e8re ligne en vie r\u00e9elle des cancers bronchiques non \u00e0 petites cellules m\u00e9tastatiques (CBNPCm)\u00a0\u2013\u00a0Donn\u00e9es issues de la cohorte KBP-2020-CPHG"],"prefix":"10.1016","volume":"113","author":[{"given":"Romain","family":"Corre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"L\u00e9na","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrien","family":"Eberlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axelle","family":"Spampinato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Guimard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Dousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Debieuvre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bulcan.2026.01.019_bib0100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jtho.2020.09.012","article-title":"Cancer du poumon en France","volume":"16","author":"Pujol","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2026.01.019_bib0105","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"24","key":"10.1016\/j.bulcan.2026.01.019_bib0110","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bulcan.2026.01.019_bib0115","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.bulcan.2026.01.019_bib0120","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.bulcan.2026.01.019_bib0125","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.bulcan.2026.01.019_bib0130","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2026.01.019_bib0135","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.bulcan.2026.01.019_bib0140","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bulcan.2026.01.019_bib0145","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.bulcan.2026.01.019_bib0150","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bulcan.2026.01.019_bib0155","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2026.01.019_bib0160","unstructured":"R\u00e9f\u00e9rentiels Auvergne Rh\u00f4ne Alpes en oncologie thoracique\u00a0: r\u00e9alis\u00e9 par l\u2019Association de Recherche d\u2019Information Scientifique et Th\u00e9rapeutique en Oncologie Thoracique (ARISTOT). https:\/\/referentiels-aristot.com\/129-cancer-bronchique-non-petites-cellules\/texte-integral-sur-le-referentiel\/."},{"key":"10.1016\/j.bulcan.2026.01.019_bib0165","unstructured":"R\u00e9f\u00e9rentiels Auvergne Rh\u00f4ne Alpes en oncologie thoracique\u00a0: cancer bronchique non \u00e0 petites cellule 16\u00e8me \u00e9dition\u00a0; https:\/\/safro-dz.org\/images\/82688.pdf."},{"key":"10.1016\/j.bulcan.2026.01.019_bib0170","doi-asserted-by":"crossref","first-page":"100492","DOI":"10.1016\/j.lanepe.2022.100492","article-title":"Lung cancer trends and tumor characteristic changes over 20 years (2000\u20132020): results of three French consecutive nationwide prospective cohorts\u2019 studies","volume":"22","author":"Debieuvre","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.bulcan.2026.01.019_bib0175","series-title":"Recommandations et r\u00e9f\u00e9rences professionnelles","author":"Matillon","year":"2000"},{"key":"10.1016\/j.bulcan.2026.01.019_bib0180","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1056\/NEJM198911093211906","article-title":"Do practice guidelines guide practice?","volume":"321","author":"Lomas","year":"1989","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bulcan.2026.01.019_bib0185","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.lungcan.2015.08.005","volume":"90","author":"Barni","year":"2015","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2026.01.019_bib0095","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13104-023-06356-5","article-title":"Clinician attitudes towards cancer treatment guidelines in Australia","volume":"16","author":"Bierbaum","year":"2023","journal-title":"BMC Res Notes"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126001335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126001335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:39:53Z","timestamp":1777592393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126001335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0007455126001335"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.01.019","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Traitements syst\u00e9miques de premi\u00e8re ligne en vie r\u00e9elle des cancers bronchiques non \u00e0 petites cellules m\u00e9tastatiques (CBNPCm)\u00a0\u2013\u00a0Donn\u00e9es issues de la cohorte KBP-2020-CPHG","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}